The Quantikine Mouse ANGPT-L3 immunoassay is a 4.5 hour solid phase ELISA designed to measure ANGPT-L3 in cell culture supernates, serum, and plasma. It contains Sf 21-expressed recombinant mouse ANGPT-L3 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural ANGPT-L3 showed linear curves that were parallel to the standard curves obtained ...using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring ANGPT-L3.
Natural and recombinant mouse ANGPT-L3. This kit detects full-length and 27 kDa N-terminal cleaved mouse ANGPT-L3 but does not detect the 38 kDa C-terminal cleavage fragment.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Mouse Angiopoietin-like 3 Quantikine ELISA Kit
Angiopoietin-like Protein 3
angiopoietin-related protein 3
Angiopoietin-like, also known as angiopoietin-related proteins, are structurally related to the angiopoietins. They are secreted proteins with N-terminal coiled-coil domains and C-terminal fibrinogen-like domains. Unlike the angiopoietins, ANGPTLs do not bind Tie-2. Seven ANGPTL proteins have been identified (ANGPTL1 through 7).
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.